Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

NCT00225212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Diffuse Large Cell Lymphoma
Mantle Cell Lymphoma
Transformed Lymphoma
Other Subtypes of B-cell Lymphoma
Lymphoma

Interventions

DRUG: Rituximab 375 mg/m2

Sponsor

Stanford University